Indication

Rare Disease

1 clinical trial

1 product

1 drug

Clinical trial

A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors

Status: Recruiting, Estimated PCD: 2026-02-01

Drug

Product